Lewy Body Dementia on Imaging
For suspected Lewy body dementia, start with noncontrast CT or MRI head to exclude mimics, then proceed to I-123 ioflupane (DaTscan) SPECT/CT as the single most important diagnostic imaging test, showing decreased dopamine transporter uptake in the striatum. 1
First-Line Structural Imaging
Begin with noncontrast CT head as the initial screening examination to exclude structural mimics such as brain tumor, subdural hematoma, or other mass lesions 1. The key supportive finding on CT is relative preservation of medial temporal lobe structures, which distinguishes DLB from Alzheimer's disease where hippocampal atrophy is prominent 1.
MRI head without contrast serves the same purpose as CT but provides superior detail. Look for:
- Preserved hippocampal and medial temporal lobe volumes compared to AD 1
- Greater subcortical atrophy (thalamus, caudate, amygdala, substantia nigra, midbrain) relative to cortical atrophy 1
- Loss of the "swallow tail sign" on susceptibility-weighted imaging (similar to Parkinson's disease) 2
Important caveat: Structural MRI changes are not helpful for differentiating DLB from other dementias on an individual patient level—they work at the group level only 1.
Most Important Diagnostic Test: Dopamine Transporter Imaging
I-123 ioflupane (DaTscan) SPECT/CT is the gold standard imaging biomarker and is listed as one of the suggestive features in current diagnostic guidelines 1. This test demonstrates:
- Decreased dopamine transporter uptake in the striatum (putamen and caudate)
- Normal uptake in Alzheimer's disease
- Low uptake in both DLB and Parkinson's disease 1
This imaging has the highest sensitivity and specificity for differentiating DLB from Alzheimer's disease based on pathological diagnoses 3, 4. The sensitivity is approximately 80% 3.
Critical pitfall: AD and DLB can coexist in the same patient, potentially confounding results 1.
Second-Line Functional Imaging
FDG-PET/CT Brain
This is a second-level examination that shows 1, 2:
- Occipital hypometabolism (the distinguishing feature from AD)
- Generalized low uptake with involvement of temporal and parietal lobes
- "Cingulate island sign": relative preservation of posterior/midcingulate metabolism compared to precuneus hypometabolism—this is highly specific for DLB 1, 2, 5
FDG-PET can distinguish between AD and DLB, with DLB showing occipital involvement while AD shows posterior cingulate and parietal hypometabolism 2, 1, 5.
Brain Perfusion SPECT (HMPAO)
Shows occipital hypoperfusion as a supportive feature 1, 5. This is less commonly used in clinical practice and has been largely replaced by other modalities 1.
Limited Utility Imaging
Amyloid PET/CT has very limited usefulness for DLB diagnosis 1. While DLB can show amyloid deposition (present in up to 29-63% of cases depending on age), the uptake is decreased compared to AD patients 2. The Society of Nuclear Medicine stated in 2024 that amyloid PET/CT is rarely appropriate in patients with DLB 2.
Practical Imaging Algorithm
- Initial evaluation: Noncontrast CT or MRI head (exclude mimics, assess medial temporal lobe preservation)
- Confirmatory test: I-123 ioflupane SPECT/CT (decreased striatal uptake confirms diagnosis)
- If DaTscan unavailable or equivocal: FDG-PET/CT (look for occipital hypometabolism and cingulate island sign)
- Consider multimodality approach: Combining MRI and SPECT has been suggested as practical for differentiating DLB from AD 1
Do not order contrast-enhanced CT or MRI for initial evaluation—it adds no diagnostic value 1.